Professor Graham Jackson discusses the importance of utilising current tools more effectively to improve early diagnosis and risk assessment in multiple myeloma as well as the future potential of novel therapies and management techniques.
Professor Antonio Palumbo reflects upon some current topics in multiple myeloma including continuous disease control to extend patient remissions, and assessment of ‘disease aggressiveness’ in multiple myeloma. Professor Palumbo also explores the efficacy of current treatments in relapsed/refractory multiple myeloma and the role of maintenance therapy.
Professor Meletios Dimopoulos, Professor Philippe Moreau and Dr Niels Van de Donk discuss the evidence currently available regarding the influence of maintenance therapy on patient outcomes in multiple myeloma and potential future treatment options.
Professor Graham Jackson and Professor Meletios Dimopoulos discuss the influence of continuous proteasome inhibitor treatment as a maintenance strategy in newly diagnosed multiple myeloma and the latest evidence from clinical trials in this treatment landscape.
Dr Niels Van de Donk and Dr Karthik Ramasamy discuss recent updates from a number of clinical studies investigating novel upfront regimens, consolidation and maintenance therapy options, as well as the potential for tandem and allograft transplantation in the management of newly diagnosed multiple myeloma patients.
Professor Gordon Cook chairs an expert debate, between Consultant Haematologists Professor Graham Jackson and Dr Karthik Ramasamy, as they discuss their thoughts on continuous therapy in multiple myeloma.
Dr Guy Pratt discusses the importance of continuous therapy as opposed to fixed duration therapy in relapsed/refractory multiple myeloma and strategies for keeping patients on long term therapy.
Dr Guy Pratt discusses the aims of the myeloma diagnosis and management NICE guidelines in the UK, published in February 2016.
Multidisciplinary team members from the Haematology department at Oxford University Hospitals discuss their roles within the team and how they work together effectively and innovatively to deliver first-class care for multiple myeloma patients.
Professor Gordon Cook discusses key issues and uncertainties concerning the treatment of patients with newly diagnosed multiple myeloma and highlights how he anticipates the treatment landscape to change to address these challenges.
Professor María-Victoria Mateos and Professor Gordon Cook discuss recent advances in the management of multiple myeloma.
Man-Chie Chow and Faouzi Djebbari, discuss their evolving role in the multidisciplinary team treating multiple myeloma patients. Dr Alberto Rocci, describes the patient benefit of the multidisciplinary team in the management of multiple myeloma.
Professor Graham Jackson and Professor Philippe Moreau discuss whether triplet therapy is realistic for all relapsed/refractory multiple myeloma patients.
Dr Stella Bowcock discusses the results of the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial and the use of antibiotic prophylaxis in improving patient outcomes in newly diagnosed patients.
Dr Charlotte Pawlyn, Professor Gordon Cook and Dr Rakesh Popat discuss the importance of using an immunomodulatory drug/proteasome inhibitor triplet in relapsed/refractory multiple myeloma.
This link opens another website that is not under the review or control of Takeda UK Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it. Please confirm you wish to continue.